07:35 AM EDT, 10/17/2024 (MT Newswires) -- Teleflex ( TFX ) said Thursday that data published in three scientific abstracts presented recently supported the safety and efficacy of its Barrigel rectal spacer, designed to reduce radiation that reaches the rectum during prostate cancer radiation therapy.

The data, gleaned from 100 men in Australia undergoing prostate cancer treatment, "demonstrate that excellent outcomes can also be achieved in real-world settings and in patients undergoing repeat radiation therapy," said Jacqueline Welch, vice president of global clinical and scientific operations at Teleflex ( TFX ).

The company said the studies found only 1 case of regional prostate cancer recurrence with a median follow-up of 1.68 years.